Role of Baicalin in Anti-Influenza Virus A as a Potent Inducer of IFN-Gamma

Ming Chu, 1,2 Lan Xu, 1,2 Ming-bo Zhang, 3 Zheng-yun Chu, 3 and Yue-dan Wang 1,2

1Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
2Key Laboratory of Medical Immunology, Ministry of Health, Beijing 100191, China
3Pharmacy Departments, Liaoning University of Traditional Chinese Medicine, Liaoning 116600, China

Correspondence should be addressed to Yue-dan Wang; wangyuedan@bjmu.edu.cn

Received 10 September 2015; Accepted 29 November 2015

Academic Editor: Gregory Tannock

Copyright © 2015 Ming Chu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Baicalin (BA) is a flavonoid compound purified from Scutellaria baicalensis Georgi and has been shown to possess a potent inhibitory activity against viruses. However, the role of BA in anti-influenza virus has not been extensively studied, and the immunological mechanism of BA in antiviral activity remains unknown. Here, we observed that BA could protect mice from infection by influenza virus A/PR/8/34 (H1N1), associated with increasing IFN-γ production, but presented no effects in IFN-γ or IFN-γ receptor deficient mice. Further study indicated that BA could inhibit A/PR/8/34 replication through IFN-γ in human PBMC. Moreover, BA could directly induce IFN-γ production in human CD4+ and CD8+ T cells and NK cells, and activate JAK/STAT-1 signaling pathway. Collectively, BA exhibited anti-influenza virus A (H1N1) activity in vitro and in vivo as a potent inducer of IFN-γ in major IFN-γ producing cells.

1. Introduction

Influenza is one of the most common respiratory diseases in human and is potentially lethal in immunocompromised persons. It affects all types of people, from infants to the elderly, and is usually caused by influenza virus A and influenza virus B. Influenza virus is an enveloped virus of the Orthomyxoviridae family, which has a unique capacity for genetic variation that is based in two molecular features of the virus family [1]. Because of the high degree of virus variability, cellular responses directed in particular against more conserved internal proteins have been investigated, involving CD4+ T cells and CD8+ T cells that are able to recognize epitopes shared by several subtypes [2, 3]. In cellular responses, IFN-γ producing cells can favor viral elimination from nasal tissues, and more generally, IFN-γ plays a critical role in cell-mediated immunity, stimulating NK cells and macrophages activity.

In mammals, the IFN system is a central innate antiviral defense mechanism, first identified in 1957 by Isaacs and Lindenmann during their seminal study on virus interference [4]. It was also the first cytokine to be purified to homogeneity, cloned, sequenced completely, and produced in recombinant form and in extensive clinical application [5]. IFN response represents an early host defense event, one that occurs prior to the onset of the adaptive immune response, produced both in the early stages of infection by NK cells and at later stages by activated CD4+ and CD8+ T cells [6]. The innate immune response to viral infection depends on the integrity of this network of cytokines, which is tightly regulated [7].

In the traditional Chinese medicine, one therapeutic use of Scutellaria is to treat cold, an illness usually caused by influenza virus infection. In 1990, a flavone isolated from the medicinal plant Scutellaria baicalensis Georgi was shown to possess a potent antiviral activity against influenza virus. Thereafter, S. baicalensis and its main constituents including BA (7-glucuronic acid, 5,6-dihydroxyflavone) were found to possess a potent inhibitory activity against various viruses [8–13]. In 2007, we first reported that the compound extract of Scutellaria could inhibit influenza virus replication and effect on inducing IFN-γ secretion in vivo, in which the content of BA was merely 7% [12]. Thereafter, we obtained pure BA from Scutellaria and confirmed its antiviral activity...
on mouse-adapted A/FM/1/47 influenza virus A (H1N1) in mice [13]. Nowadays, BA was documented to exert its anti-influenza activity by modulating viral protein NS1-mediated cellular innate immune responses [11]. In this paper, we further studied the direct effects of BA on immune systems, including CD4+ and CD8+ T cells and NK cells. We believe that further study in the antiviral activity of BA will aid in our ability to design effective interventions and treatments for viral prevention and therapy.

2. Materials and Methods

2.1. Animals. 4–6-week IFN-γ −/− knockout (KO), IFN-γ receptor −/− KO, and +/+ wild-type (WT) mice (all on a C57BL/6 background) were obtained from the Jackson Laboratory (Bar Harbor, ME) and kept in a pathogen-free environment.

2.2. Virus. Mouse-adapted strain of human influenza virus A/PR/8/34 (H1N1) was obtained from the Chinese Center for Disease Control and Prevention and adapted to growth in MDCK cells. Stock virus was stored at −80°C until use.

2.3. Reagent. BA was isolated and prepared by procedures elsewhere [12, 13], provided by Liaoning University of Traditional Chinese Medicine. Its structure has been determined to be 7-D-glucuronic acid-5,6-dihydroxyflavone (mp 223°C and λ max 276).

2.4. Cells. MDCK cells were obtained from ATCC and expanded at 37°C in a humidified atmosphere of 5% CO2 and 95% air in MEM (Invitrogen) containing 10% newborn calf serum (GIBCO-BRL). Mouse CD4+ and CD8+ T cells and NK cells were isolated to >95% purity by automated magnetic negative selection using EasySep mouse CD4+ and CD8+ T cells and NK cells enrichment kits (StemCell Technologies Inc.) from spleen cells of experimental C57BL/6 mice. Human PBMC were obtained by centrifugation heparrized blood on Lymphoprep gradient and recovered from the gradient and washed first with saline and twice in RPMI 1640 (GIBCO-BRL) plus glutamine-streptomycin-penicillin (GSP) and 5% fetal bovine serum (FBS). Human CD4+ and CD8+ T cells and NK cells were isolated to >95% purity by automated magnetic negative selection using EasySep human CD4+ and CD8+ T cells and NK cells enrichment kits (StemCell Technologies Inc.) from PBMC of healthy volunteers.

2.5. Experimental Infection and Treatment of Mice. Mice were infected intranasally with 0.1 LD50 (5 × 104 PFU/mL) of A/PR/8/34 in 100 μL PBS [14]. Infected mice were treated with various concentrations of BA at 1.0 g/kg, 1.5 g/kg, or 2.0 g/kg every 24 h for 14 days. Infected mice were then treated with the compound solutions prepared in PBS (pH = 7.2) by intragastric administration. Ten infected mice were used for each treatment and control regimen. Mouse survival rate was determined. Weight and clinical signs of infection (evidenced by fever, trembling, and weak respiration) were recorded daily for a period of 2 weeks.

2.6. Lung Virus Titers. Lungs of the infected mice treated with various concentrations of BA were removed on days 3, 5, and 7. Viral titers in lungs were determined using a modified MDCK cell plaque assay [15]. Mice lungs were harvested into 1 mL DMEM media, homogenated, serially diluted, and added to duplicate confluent monolayers of MDCK cells for 1 h at 37°C. Each well was then covered with 1 mL of agar overlay (DMEM plus 0.2% BSA, 2 mg/mL NaHCO3, 2 mM Heps, PEG, 0.5% agar, 0.01% DEAE dextran, and 0.5 μg/mL trypsin; Sigma-Aldrich). After 2-3 days of incubation at 37°C, cells were fixed with 0.5 mL of Carnoy’s fixative and stained with 2% crystal violet in 20% ethanol (Sigma-Aldrich). PFU/mL = (mean number of plaques/0.1) × (1/dilution factor) [14].

2.7. Histology. On day 7 after infection, mice were injected with 3 mg pentobarbital and exsanguinated. The trachea was exposed and 1 mL of 2% formalin was instilled into the lungs. The inflated lungs were removed and placed in tubes containing 5 mL of 2% formal saline. Samples were embedded in paraffin and sections were stained with hematoxylin and eosin for histological analysis [16].

2.8. ELISA. IFN-γ in the mice serum and cell culture supernatants was detected by double layer ELISA. A 96-well plate was coated with antibody against IFN-γ (1:2,000; Santa Cruz, Goat) in 50 μL PBS/well for 1 h at 37°C. The wells, after three successive washings with PBS, were incubated with 0.25% BSA and 0.05% Tween 20 in PBS for 30 min. Cell culture supernatants were serially diluted (from 1:10) with PBS containing 0.25% BSA and 0.05% Tween 20 were added to the wells and incubated for 1 h at 37°C. After washing, 0.25% BSA and 0.05% Tween 20 in PBS were again added to each well and incubated for 10 min at 37°C. Anti-IFN-γ-HRP (1:5,000; Santa Cruz, Rabbit) was added and the plate incubated for 1 h at 37°C. After final washing, the plate was developed with o-phenylenediamine in a buffer containing 0.012% hydrogen peroxide, 0.1 M citric acid, and 0.1 M NaHPO4. The plates were then read at 570 nm and the sample concentrations were determined from a standard curve [17].

2.9. ELISPOT. We coated 96-well nitrocellulose-based plates (MAHA S45; Millipore) with 5 μg of anti-mouse IFN-γ mAb/mL diluted in carbonate buffer (100 μL/well). The plates were kept overnight at 4°C. Wells were then blocked with AIMV containing GSP for 1 h at 35°C. The cells were resuspended in AIMV and added to the wells (1 × 106 cells/50 μL per well, in triplicate for each condition) and incubated for 24 h at 37°C in 5% CO2. After incubation, the plates were extensively washed first with PBS and then with PBS-0.05% Tween (PBST) to detach and remove cells. Individual wells were then treated with 100 μL of biotin-conjugated anti-mouse IFN-γ (1 μg/mL), and the plates were incubated for 2 h at room temperature (RT). The plates were washed with PBST and then incubated with streptavidin-peroxidase (0.5 μg/mL; Southern Biotechnology) for 1 h at RT. After an extensive washing with PBST and PBS, spots corresponding to IFN-γ producing cells were visualized with 3-amino-9-ethylcarbazole in 0.1 M sodium acetate (pH = 5.0). Spots were counted with an automated ELISPOT plate counter.
(Microvision Instruments), and values corresponded to the mean number of spots (in triplicate) for 1 × 10⁶ cells. Final values were obtained by subtraction of the control values (without stimulation). The mean value for negative controls according to the different experiments was a maximum of 1 spot/well, corresponding to 10 spots/million cells [18].

2.10. RT-PCR Analysis. Total RNA (2.5 μg) was extracted using Trizol Reagent (Life Technologies, Inc.), and then RNA was reverse-transcribed with 20 U of reverse transcriptase using the Sensiscript RT Kit (Qiagen) with oligo (dT) primer [19]. After reverse transcription, 1 μL of each reverse transcription reaction was used for PCR with Taq Polymerase (TaKaRa). The specific primers used to RT-PCR reverse transcription reaction was used for PCR with Taq polymerase. The statistical significance of the RT-PCR analysis was determined using Student’s t-test. Survival probability statistics were used to analyze the survival rates. Data were regarded as statistically significant at P < 0.01.

2.12. Experimental Infection and Treatment of PBMC. PBMC infected with A/PR/8/34 were collected by centrifugation, suspended in PBS, centrifuged, and then suspended in 1 mL of infected allantoic fluid diluted to provide a multiplicity of 10 to 20 plaque-forming units per cell. The cultures were rotated gently for 60 min at RT during adsorption. After virus adsorption, the inoculum was removed from the cells, the cultures were washed once with PBS, and then PBMC were suspended in 1 mL of medium (1 × 10⁶ to 2 × 10⁶ cells per mL). A/PR/8/34 infected PBMC were treated with gradient of concentration of BA at 0 μM, 0.1 μM, 1 μM, 10 μM, 100 μM, and 1 mM for 48 h at 37°C.

2.13. Oligodeoxynucleotide Treatment of Cells. The oligodeoxynucleotides were the same as described [22–25] and were as follows: oligo I, 5'-GGG GTG TGT GGT GGG TGT GTG-RNH₂; oligo II, 5'-AC ACA ACA CCC AAG ACA ACC AAC CCC-RNH₂. PBMC infected with A/PR/8/34 were treated with (a) PBS, (b) 1 mM BA, (c) 1 mM BA and 25 μM oligo I, and (d) 1 mM BA and 25 μM oligo II. Viral titers were detected at 12 h, 24 h, 36 h, 48 h, 60 h, and 72 h.

2.14. Viral Titers Detection. Viruses in the PBMC culture supernatant were collected and then titrated by use of an MDCK plaque assay described previously [14, 15]. The percent inhibition rate was calculated by using the following formula: % Inhibition = (1 – Infectivity titer of BA treated virus/infective titer of nontreatment virus) × 100%.

2.15. Statistical Analysis. All experiments were performed at least three times and the results are from representative experiments. The statistical significance was determined using Student’s t-test. Survival probability statistics were used to analyze the survival rates. Data were regarded as statistically significant at P < 0.01.

3. Results

3.1. Antiviral Activity of BA in Treating A/PR/8/34-Infected Mice. As described previously, we found that both the compound extract of Scutellaria (BA ≥ 7%) and pure BA exhibited an inhibitory activity on mouse-adapted A/FM/1/47 influenza virus A [12, 13]. To further systematically investigate the anti-influenza activity of BA, we examined its effect on mouse-adapted strain of human influenza virus A/PR/8/34 in mice.

We inoculated 4–6-week-old C57BL/6 mice with 0.1 LD₅₀ (5 × 10⁵ PFU/mL) of A/PR/8/34 in 100 μL PBS. All the A/PR/8/34 infected mice without BA treatment died on the 8th day following infection. After being treated with 1.0 g/kg, 1.5 g/kg, and 2.0 g/kg BA, 70, 80, and 80 percent of the infected mice survived to the 8th day following infection, respectively. Moreover, the survival rate in the BA treatment groups was found for 60, 70, and 80 percent 14 days after infection, which were significantly higher than those for mice without BA treatment (P < 0.01, Figure 1(a)). Meanwhile, A/PR/8/34-infected mice without BA treatment lost 15.66 ± 2.88% of their body weight, whereas those in the BA treatment group maintained or increased their weight.

In addition, in the untreated mice, virus titers increased to 10⁵–⁶ PFU/mL on the 7th day. In contrast, virus titers in the 1.0 g/kg, 1.5 g/kg, and 2.0 g/kg BA treated mice lungs decreased to 10⁵, 10⁴, and 10¹⁰ PFU/mL, respectively (Figure 1(b)). Furthermore, hemagglutination titers of the untreated mice lungs were 1:640, obviously higher than 1:80 in the BA treated mice groups, indicating that BA has an inhibitory activity on A/PR/8/34 replication in mice lungs. We observed that the C57BL/6 wild type mice’s lungs of the infected and untreated mice swelled and became red due
3.2. Effects of BA on IFN-γ Production in A/PR/8/34-Infected Mice. In the previous study, we observed that the compound extract of *Scutellaria* (BA ≥ 7%) had an effect on inducing IFN-γ secretion in mice [12]; however, the effect of pure BA on IFN-γ production remains unclear. Thus, we further investigated the effects of BA on IFN-γ production in mice PBMC, and mice IFN-γ producing cells, including CD4+ and CD8+ T cells and NK cells.

First, we detected the concentration of IFN-γ in the mouse serum on day 7 by ELISA and found that BA could obviously induce IFN-γ secretion ($P < 0.01$, Figure 2(a)). Then, we evaluated the numbers of IFN-γ positive cells in mice PBMC using ELISPOT. As shown in Figure 2(b), IFN-γ positive cells significantly increased in the PBMC of mice treated with 1.0 g/kg, 1.5 g/kg, and 2.0 g/kg BA, compared to the control A/PR/8/34 infected mice and untreated mice. Thereafter, we focused our study on the mice IFN-γ producing cells, including CD4+ and CD8+ T cells and NK cells. RT-PCR results showed that the IFN-γ transcripts in the mice CD4+ and CD8+ T cells and NK cells increased in the BA treatment group (Figure 2(c)). Meanwhile, the production of IFN-γ also increased significantly in CD4+ and CD8+ T cells and NK cells in the BA treated mice (Figure 2(d)). Collectively, we found that BA could generally enhance IFN-γ synthesis and secretion in the IFN-γ producing cells in mice PBMC, including CD4+ and CD8+ T cells and NK cells.

3.3. Effects of BA in Treating A/PR/8/34-Infected IFN-γ or IFN-γ Receptor KO Mice. Due to our preliminary study, IFN-γ might be responsible for the anti-influenza virus activity of BA [13]. To confirm our hypothesis, we evaluated whether to congestion. However, lungs of the infected mice treated with BA remained grayish white and were not congested. In the further study, performed by histological analysis, we observed that BA was able to resist A/PR/8/34 infection through regulating inflammatory responses, so as to prevent the formation of pulmonary fibrosis. Meanwhile, BA could also inhibit inflammatory lesion in mice lung tissues after A/PR/8/34 infection (Figure 1(c)).
BA has a protective effect in IFN-γ (or receptor) knockout mice. We inoculated 4–6-week-old mice with 0.1 LD$_{50}$ (5 x 10$^3$ PFU/mL) of A/PR/8/34 in 100 μL PBS. As we expected, all infected IFN-γ $^{-/-}$ mice or IFN-γ receptor $^{-/-}$ mice treated with 2.0 g/kg BA died on the 8th day following infection (Figure 1(a)). In contrast, the survival rate in the 2.0 g/kg BA treated WT mice was found for 80 percent 14 days after infection ($P < 0.01$, Figure 3(a)). In addition, in the IFN-γ and IFN-γ receptor KO mice, virus titers increased to 10$^6.8$ and 10$^7.1$ PFU/mL, respectively, on the 7th day, even higher than that in the control infected WT mice. In contrast, virus titers in the 2.0 g/kg BA treated mice decreased to 10$^{3.1}$ on day 7 after infection (Figure 3(b)). Furthermore, we observed that BA could not inhibit A/PR/8/34 infection in the IFN-γ (or receptor) KO mice, which suggests that the antiviral activity of BA is associated with IFN-γ (Figure 3(c)).

3.4. Antiviral Activity of BA on A/PR/8/34 Replication in Human PBMC through Induction of IFN-γ. To confirm the anti-A/PR/8/34 virus activity of BA in human, we obtained
PBMC from healthy volunteers. Then, we infected human PBMC with A/PR/8/34 and treated the infected PBMC with gradient concentration of BA at 0 μM, 0.1 μM, 1 μM, 10 μM, 100 μM, and 1 mM for 48 h at 37°C, to observe the inhibitory effect of BA on influenza virus.

To evaluate the anti-A/PR/8/34 virus activity of BA in vitro, we determined the virus titers by use of an MDCK plaque assay. As shown in Figure 4(a), a dose-dependent inhibition of A/PR/8/34 virus was observed after treating the infected PBMC with BA. Presence of 100 μM BA in PBMC yielded 30% inhibition and about 60% was inhibited by 1 mM BA (P < 0.01). In addition, the replication of A/PR/8/34 was significantly inhibited in the presence of 100 μM and 1 mM BA (Figure 4(b)). To further assess the antiviral activity of BA in vitro, we examined the virus growth kinetics in PBMC treated with or without 1 mM BA. A/PR/8/34 in PBMC treated with 1 mM BA grew significantly worse than nontreatment. The peak viral titer reached 10^3.9 PFU/mL at 48 hours after infection (h.p.i.) for A/PR/8/34 treated with 1 mM BA, compared to 10^7.9 PFU/mL at 48 h.p.i. for nontreatment (P < 0.01, Figure 4(c)). In addition, using the high affinity IFN-γ aptamers, we found that the antiviral activity of 1 mM BA was significantly suppressed by 25 μM oligo I, taking oligo II as negative control (Figure 4(c)).

Meanwhile, we tested the IFN-γ synthesis in human PBMC after different treatment and found that BA was able to enhance IFN-γ transcription at a high concentration of 100 μM to 1 mM under A/PR/8/34 virus infection (Figure 5(a)). In the further examination, we observed the effect of BA on IFN-γ production in the cytosol protein of PBMC by Western Blotting. As shown in Figure 5(b), there was no significant difference in IFN-γ production in PBMC after being treated with 0.1 μM to 10 μM BA. However, BA, at a high concentration of 100 μM to 1 mM, had an obvious influence on IFN-γ protein expression, similar to the transcriptional level. Then, we investigated the secretion of IFN-γ in PBMC cell culture supernatants. As a result, we found that the influence of BA on IFN-γ secretion exhibited a dose-dependent manner; BA was able to increase IFN-γ secretion significantly at a concentration from 100 μM to 1 mM under A/PR/8/34 virus infection (Figure 5(c)). Interestingly, when human PBMC were treated with BA without
Figure 4: Antiviral activity of BA on A/PR/8/34 replication in human PBMC. A/PR/8/34 infected PBMC were treated with gradient concentration of BA at 0 \( \mu M \), 0.1 \( \mu M \), 1 \( \mu M \), 10 \( \mu M \), 100 \( \mu M \), and 1 mM for 48 h at 37°C. (a) Viruses in the culture supernatants were collected and then titrated by use of an MDCK plaque assay to determine the virus titers. The percent inhibition rate was calculated by using the following formula: % Inhibition = (1 − Infective titer of BA treated virus/infective titer of nontreatment virus) × 100%. (b) Total RNA was isolated from PBMC and subjected to RT-PCR. The RT-PCR of A/PR/8/34 was analyzed on 1% agarose gel electrophoresis. (c) Viral titers of A/PR/8/34 in PBMC treated with PBS (○), 1 mM BA (□), 1 mM BA with 25 \( \mu M \) oligo I (◆), and 1 mM BA with 25 \( \mu M \) oligo II (▲) were determined at 12, 24, 36, 48, 60, and 72 h.p.i. Each data shows mean ± SE of three respective determinations. * Levels of significance of \( P < 0.05 \) against control infected PBMC, ** levels of significance of \( P < 0.01 \) against control infected PBMC cells.
**Figure 5:** Effects of BA on IFN-γ production in human PBMC. A/PR/8/34 infected PBMC were treated with gradient concentration of BA at 0 μM, 0.1 μM, 1 μM, 10 μM, 100 μM, and 1 mM for 48 h at 37°C. (a) Total RNA was isolated from PBMC and subjected to RT-PCR. The RT-PCR of human IFN-γ products was analyzed on 1% agarose gel electrophoresis. (b) The cytosol proteins were obtained from PBMC and analyzed by Western Blotting with anti-IFN-γ antibody. (c) IFN-γ production in cell culture supernatant infected with (c) or without (d) A/PR/8/34 virus infection was calculated by ELISA, and the results were determined from a standard curve. * Levels of significance of $P < 0.05$, ** levels of significance of $P < 0.01$.

**Figure 6:** Effects of BA in JAK/STAT-1 pathway. Human PBMC were treated with or without 1 mM BA for 24 h, 48 h, and 72 h at 37°C. (a) The cytosol protein was separated by electrophoresis in a 12.5% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. The proteins were blotted with anti-JAK-1, anti-JAK-2, anti-phosphotyrosine 4G10, and anti-phospho-JAK-2-Y1007/Y1008 Abs, respectively. (b) The nucleus proteins (upper panels) and cytosol proteins (lower panels) were obtained and analyzed by Western Blotting using Abs against STAT-1, phosphor-STAT-1 (tyrosine 701), and phosphor-STAT-1 (serine 727).

In order to investigate the effects of BA on IFN-γ transcription in CD4+ and CD8+ T cells and NK cells, we harvest cells treated or untreated with 1 mM BA for 24 h, 48 h, and 72 h. Total RNA was isolated and subjected to RT-PCR with specific human IFN-γ primers. The results shown in Figure 7(a) represented that BA promote IFN-γ mRNA expression in CD4+ and CD8+ T cells and NK cells and exhibited a continuous effect for 24 h to 72 h. We next examined whether BA could enhance IFN-γ protein expression in the cytosol protein. Western Blotting results showed that BA promoted IFN-γ protein synthesis in CD4+ and CD8+ T cells and NK cells in the cytosol protein and exhibited a sustained action for 24 h to 72 h, similar to the transcriptional level (Figure 7(b)). In the study of IFN-γ secretion, we used ELISA assay to evaluate its concentration in the culture supernatants of CD4+ and CD8+ T cells and NK cells treated with 1 mM BA. Untreated cell culture supernatants were used as negative control. The results showed that the IFN-γ protein in the supernatants increased for 24 h to 72 h, and the treated group was kept at a higher level, compared to untreated group ($P < 0.01$, Figure 7(c)), which indicated that BA was able to induce IFN-γ secretion. In summary, we proved that BA was able to enhance IFN-γ synthesis and secretion in human CD4+ and CD8+ T cells and NK cells.

4. Discussion

Influenza is still a major health burden, and options for the control and treatment of the disease are limited, because of the high degree of virus variability, requiring annual
vaccination [30]. Thus, there is an urgent public health need to develop effective drugs against various influenza viruses.

In eastern countries, *Scutellaria baicalensis* Georgi has been used to treat influenza for centuries and proved to be effective and safe, but the antiviral mechanism remains unknown. Thus, we first extracted the compound of *Scutellaria baicalensis* Georgi and examined its antiviral activity against a mouse-adapted influenza virus A/FM/1/47. As we expected, the compound had an effect on inhibiting influenza virus replication in mice; meanwhile, we found that this compound might also induce IFN-γ secretion [12]. It is known that the compound isolated from *Scutellaria baicalensis* Georgi contains four major flavones: Wogonin, Wogonoside, Baicalein, and BA with ratios to the dry material about 1.3%, 3.55%, 5.41%, and 10.11%, respectively [31]. As a main component in *Scutellaria baicalensis* Georgi, BA has a variety of beneficial effects including antiviral activities [8]. In particular, the anti HTLV-1 and HIV-1 effect of BA have been documented [9–11]. However, the role of BA in anti-influenza virus activity has not been extensively studied. In the further study, we identified the inhibitory effect of BA on A/FM/1/47 replication in mice for the first time and demonstrated that BA could significantly induce IFN-γ secretion in mice serum [12, 13]. Thus, we believe that IFN-γ plays an important role in the antiviral action of BA.

Based on the previous research, we first identified the antiviral activity of BA in treating A/PR/8/34-infected mice and observed that BA was able to attenuate A/PR/8/34 associated death and inhibit virus replication in mice lungs. To verify that IFN-γ is responsible for the antiviral activity of BA, we tested whether BA could protect IFN-γ −/− mice and IFN-γ receptor −/− mice from A/PR/8/34 infection. As expected, BA possessed no anti-influenza virus effect in IFN-γ (or receptor) knockout mice, which prompted that the antiviral activity of BA is associated with its effect on IFN-γ production.

The IFN-γ is a pleiotropic cytokine mainly secreted by CD4+ and CD8+ T cells and NK cells and has been believed to be a first line of host defense in the control of viral infections [32]. Considering the antiviral activity of BA correlated with IFN-γ, we focused our study on its IFN-γ inducing action. In evaluating the IFN-γ secretion in mice serum, significant
increases of IFN-γ were detected in the mice treated with BA at an effective concentration. In addition, BA could also increase the percent of IFN-γ positive cells in mice PBMC. Since CD4+ and CD8+ T cells and NK cells are the major IFN-γ producing cells in PBMC, we wondered if BA could directly induce IFN-γ production in all these cells. As expected, the transcription of IFN-γ mRNA increased in mice CD4+ and CD8+ T cells and NK cells, which resulted in the increases of IFN-γ production. These findings prompted a general action of BA on inducing IFN-γ synthesis in mice IFN-γ producing cells.

To further validate these effects of BA in human PBMC, we first used 0.1 μM to 1 mM BA to investigate its inhibitory actions on A/PR/8/34 infection in vitro. Similarly to the results in vivo, BA exhibited anti-A/PR/8/34 replication activity in a dose-dependent manner and significantly reduced A/PR/8/34 infective titers at a concentration of 1 mM. More importantly, the antiviral activity of BA was suppressed by the high affinity IFN-γ aptamers, which confirmed that IFN-γ is responsible for the antiviral activity of BA [33]. Meanwhile, BA could apparently enhance IFN-γ production in human PBMC, especially at 100 μM to 1 mM. Since CD4+ and CD8+ T cells and NK cells, especially at 100 μM to 1 mM BA, were detected in the mice treated with BA, we wondered if BA could directly induce IFN-γ production in human PBMC, we then examined the representative changes during the activation process. We found that the JAK/STAT-1 signaling pathway plays an important role in human PBMC, which is enhanced by BA in vitro. The results are consistent with the previous findings that BA could apparently enhance IFN-γ production in human PBMC, especially at 100 μM to 1 mM BA. According to the general IFN-γ inducing action of BA in mice, we further confirmed the effects of BA in human CD4+ and CD8+ T cells and NK cells using 1 mM BA. Several methods were used to verify the activity of BA on inducing IFN-γ expression and secretion. As a result, BA could enhance IFN-γ production at 1 mM in human CD4+ and CD8+ T cells and NK cells and possessed a sustained action for 24 h to 72 h. Recent studies indicated that the action of BA in inducing IFN-γ production of T cells might be mediated by TCR (α/β) [33]. Collectively, BA could generally induce IFN-γ production in mice and human IFN-γ producing cells, so as to resist various viruses, including influenza virus.

Two main problems of present therapy that play a major role in treatment of influenza are the high degree of virus variability and the reorganization of various viruses. Effective vaccine is important in the prevention of influenza; however, it could not be effective against new generated influenza virus. Thus, it is urgent to develop broad-spectrum antiviral drugs. In this report, we found that BA exhibited anti-influenza virus A (H1N1) activities in vivo and in vitro through upregulation of IFN-γ production in CD4+ and CD8+ T cells and NK cells. It has been determined that IFN is a strong activator, produced both in the early stages and later stages of viral infection, and plays an important role in innate immune response. Therefore, the antiviral activity of BA might not be restricted in the species of virus, which makes it a potent therapy in treating various influenza viruses. Moreover, BA, purified from Scutellaria baicalensis Georgi, has been used in the treatment of several diseases and proved to be safety [34]. Thus, development in the study of BA in antiviral activities may constitute a new safe approach for viral prevention and therapy.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution
Ming Chu and Yue-dan Wang conceived the experiments, Ming Chu, Lan Xu, and Ming-bo Zhang conducted the experiments, and Zheng-yun Chu analyzed the results. Ming Chu prepared the figures and wrote the main paper text. All authors reviewed the paper.

Acknowledgments
This work was supported by Leading Academic Discipline Project of Beijing Education Bureau (BMU20110254) and the fund for Fostering Talents in Basic Science of the National Natural Science Foundation of China (J1030831/J10108).

References
[1] E. D. Kilbourne, “Influenza pandemics of the 20th century,” Emerging Infectious Diseases, vol. 12, no. 1, pp. 9–14, 2006.
[2] D. Meng, Y. Hu, C. Xiao, T. Wei, Q. Zou, and M. Wang, “Chronic heat stress inhibits immune responses to H5N1 vaccination through regulating CD4+CD25+Foxp3+ Tregs,” BioMed Research International, vol. 2013, Article ID 168059, 14 pages, 2013.
[3] E. M. Parzych, L. J. Dimenna, B. P. Latimer et al., “Influenza virus specific CD8+ T cells exacerbate infection following high dose influenza challenge of aged mice,” BioMed Research International, vol. 2013, Article ID 876314, 14 pages, 2013.
[4] A. Isaacs and J. Lindenmann, “Pillars Article: Virus interference. I. The interferon,” Proc R Soc Lond B Biol Sci. 1957: 147: 258–267,” The Journal of Immunology, vol. 195, no. 5, pp. 1911–1920, 2015.
[5] A. Billiau, “Interferon: the pathways of discovery. I. Molecular and cellular aspects,” Cytokine & Growth Factor Reviews, vol. 17, no. 5, pp. 381–409, 2006.
[6] S. Vollstedt, S. Arnold, C. Schwerdel et al., “Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1,” Journal of Virology, vol. 78, no. 8, pp. 3846–3850, 2004.
[7] L. Malmgaard and S. R. Paludan, “Interferon (IFN)-α/β, interleukin (IL)-12 and IL-18 coordinately induce production of IFN-γ during infection with herpes simplex virus type 2,” The Journal of General Virology, vol. 84, no. 9, pp. 2497–2500, 2003.
[8] Q. Guo, L. Zhao, Q. You et al., “Anti-hepatitis B virus activity of wogonin in vitro and in vivo,” Antiviral Research, vol. 74, no. 1, pp. 16–24, 2007.
[9] H.-Y. Zhu, L. Han, X.-L. Shi et al., “Baicalin inhibits autophagy induced by influenza A virus H3N2,” Antiviral Research, vol. 113, pp. 62–70, 2015.
[10] Q. Wan, H. Wang, X. Han et al., “Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus,” Biomedical Reports, vol. 2, no. 3, pp. 437–441, 2014.
[11] M. K. Nayak, A. S. Agrawal, S. Bose et al., “Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses,” The...
M. Chu, Z.-Y. Chu, and D.-D. Wang, "The extract of compound Radix Scutellariae on mRNA replication and IFN expression of influenza virus in mice," Zhong Yao Cai, vol. 30, no. 1, pp. 63–65, 2007.

Z.-Y. Chu, M. Chu, and Y. Teng, "Effect of baicalin on in vivo anti-virus," Zhongguo Zhong Yao Za Zhi, vol. 32, no. 22, pp. 2413–2415, 2007.

D. M. Jelley-Gibbs, D. M. Brown, J. P. Dibble, L. Haynes, S. M. Eaton, and S. L. Swain, "Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation," The Journal of Experimental Medicine, vol. 202, no. 5, pp. 697–706, 2005.

K. Tobita, A. Sugiuara, C. Enomoto, and M. Furuyama, "Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin," Medical Microbiology and Immunology, vol. 162, no. 1, pp. 9–14, 1975.

G. Walzl, S. Tafuro, P. Moss, P. J. M. Openshaw, and T. Russell, "Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology," The Journal of Experimental Medicine, vol. 192, no. 9, pp. 1317–1326, 2000.

X. Y. Qiu, X. H. Zhu, L. Zhang et al., "Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells," Cancer Research, vol. 63, no. 19, pp. 6488–6495, 2003.

C. Dercamp, V. Sanchez, J. Barrier, E. Trannoy, and B. Guy, "Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay," Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 2, pp. 230–235, 2002.

M. Chu, R. Ding, Z.-Y. Chu et al., "Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor," BMC Complementary and Alternative Medicine, vol. 14, article 89, 2014.

Y.-K. Shin, Q. Liu, S. K. Tikoo, L. A. Babiuk, and Y. Zhou, "Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation," The Journal of General Virology, vol. 88, no. 3, pp. 942–950, 2007.

S.-H. Kim, J. Oh, J.-Y. Choi, J.-Y. Jang, M.-W. Kang, and C.-E. Lee, "Identification of human thioredoxin as a novel IFN-gamma-induced factor: mechanism of induction and its role in cytokine production," BMC Immunology, vol. 9, article 64, 2008.

M. Chu, J. R. Kang, W. Wang et al., "Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific aptamer," Cellular & Molecular Immunology, 2015.

M. Ramanathan, M. Lantz, R. D. MacGregor et al., "Inhibition of interferon-γ-induced major histocompatibility complex class I expression by certain oligodeoxynucleotides," Transplantation, vol. 57, no. 4, pp. 612–615, 1994.

M. Ramanathan, M. Lantz, R. D. MacGregor, M. R. Garovoy, and C. A. Hunt, "Characterization of the oligodeoxynucleotide-mediated inhibition of interferon-gamma-induced major histocompatibility complex class I and intercellular adhesion molecule-1" The Journal of Biological Chemistry, vol. 269, no. 40, pp. 24564–24574, 1994.